Sonoma Pharmaceuticals (NASDAQ:SNOA) Share Price Passes Above Two Hundred Day Moving Average – Here’s What Happened

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.29 and traded as high as $2.85. Sonoma Pharmaceuticals shares last traded at $2.66, with a volume of 151,920 shares.

Sonoma Pharmaceuticals Trading Down 1.1 %

The company has a market cap of $3.56 million, a price-to-earnings ratio of -0.53 and a beta of 1.41. The business has a fifty day moving average of $2.71 and a two-hundred day moving average of $2.29.

Sonoma Pharmaceuticals (NASDAQ:SNOA) last released its quarterly earnings results on Thursday, November 7th. The company reported ($0.59) earnings per share for the quarter. Sonoma Pharmaceuticals had a negative return on equity of 59.58% and a negative net margin of 27.21%. The business had revenue of $3.58 million during the quarter. On average, research analysts forecast that Sonoma Pharmaceuticals, Inc. will post -4 EPS for the current fiscal year.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

A hedge fund recently bought a new stake in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC purchased a new stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned approximately 1.08% of Sonoma Pharmaceuticals at the end of the most recent reporting period. 1.95% of the stock is currently owned by hedge funds and other institutional investors.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.